Xenetic Biosciences Inc. | Ownership
Companies that own Xenetic Biosciences Inc.
Royal Bank of Canada (Channel Islands) Ltd.
323,883
3.44%
0
0.04%
06/30/2018
BMO Asset Management, Inc.
10,000
0.11%
10,000
0%
06/30/2018
PanAgora Asset Management, Inc.
6,197
0.07%
-2,335
0%
06/30/2018
Morgan Stanley & Co. LLC
3,137
0.03%
1,100
0%
06/30/2018
Resources Investment Advisors, Inc.
452
0.01%
0
0%
06/30/2018
UBS Securities LLC
49
0%
-2,533
0%
06/30/2018
Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)
2
0%
2
0%
06/30/2018
DWS Investment GmbH
0
0%
-2,372
0%
06/30/2018
Citadel Advisors LLC
0
0%
-11,682
0%
06/30/2018
| Address |
40 Speen Street
Framingham Massachusetts 01701
United States
|
|
Employees
|
- |
| Website |
http://www.xeneticbio.com |
| Updated |
07/08/2019 |
| Xenetic Biosciences, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of next generation biologic drugs and novel orphan oncology therapeutics. Its lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod), which focuses on the treatment of progesterone resistant endometrial cancer. It also offers proprietary drug development platform, PolyXen, which enables next-generation biologic drugs by improving their half-life and other pharmacological properties. |
